- enrolling by invitationPHASE3
Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
This study looks at the long-term safety and effectiveness of treatments (BIIB111 and BIIB112) for two rare eye conditions, Choroideremia (CHM) and X-Linked Retinitis Pigmentosa (XLRP). It's for men who have already received one of these treatments in a previous study.
United States · Brazil · Canada - active not recruitingPHASE2
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
This study is for people who have already had gene therapy for an eye condition called X-linked Retinitis Pigmentosa (XLRP). It looks at how safe and effective the same treatment is when given to their other eye, and how they get on with it over time.
United States · United Kingdom - active not recruitingPHASE3
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
This study is looking into a new gene therapy called AAV5-hRKp.RPGR for X-linked retinitis pigmentosa (XLRP). It's for people aged 3 and over with this eye condition, aiming to see if it can help improve or protect their vision. This is a follow-up trial.
United States · Belgium · Canada - active not recruitingPHASE2, PHASE3
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
This study checks a new gene therapy, AGTC-501, for young men with an eye condition called X-linked retinitis pigmentosa (XLRP). It aims to see if it's safe and helps improve their eyesight, comparing two doses to an untreated group.
United States · Australia · Canada - completedPhase II
A follow-on study for second-eye treatment for participants previously treated with gene therapy for X-Linked Retinitis Pigmentosa (XLRP)
This study is for men with a serious eye condition called X-linked Retinitis Pigmentosa (XLRP) who have already received gene therapy in one eye. It aims to see if giving the same treatment to their second eye is safe and how well it's tolerated, hoping to improve or protect their vision.
United Kingdom